RGNX Shares Outstanding History



Below is a table of the RGNX shares outstanding history going back to 9/17/2015:

Date RGNX Shares Outstanding
9/17/201524.61M
11/5/201526.31M
3/1/201626.33M
5/4/201626.34M
8/5/201626.47M
11/4/201626.48M
3/3/201726.51M
5/5/201730.82M
8/4/201730.89M
11/3/201731.15M
3/2/201831.66M
5/4/201831.94M
8/3/201832.31M
11/2/201835.84M
2/22/201936.42M
5/3/201936.64M
8/2/201936.81M
11/1/201936.87M
2/21/202037.14M
5/1/202037.24M
7/31/202037.33M
10/30/202037.41M
2/25/202142.50M
4/30/202142.51M
8/4/202142.60M
10/28/202142.77M
12/31/202142.95M
4/28/202243.13M
7/27/202243.23M
10/27/202243.29M
2/23/202343.46M
4/27/202343.47M
7/27/202343.96M
11/2/202343.99M
2/22/202444.43M
5/2/202449.26M
7/25/202449.42M

Also see: RGNX Market Cap History
RGNX YTD Return
RGNX Historical Shares Outstanding:
+8.19% CAGR
RGNX Historical Shares Outstanding: +8.19% CAGR

Mouse over chart for data details
9/17/2015 ...7/25/2024
REGENXBIO is a clinical-stage biotechnology company. Co.'s product candidates include: RGX-314, which is being developed as a gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other additional chronic retinal conditions which cause total or partial vision loss for patients in the U.S., Europe and Japan; RGX-121, which is for the treatment of Mucopolysaccharidosis Type II; RGX-111, which is for the treatment of Mucopolysaccharidosis Type I; RGX-181, which is for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease; and RGX-381, which is for the treatment of ocular manifestations of CLN2 disease. We show 37 historical shares outstanding datapoints in our coverage of RGNX's shares outstanding history.

Understanding the changing numbers of RGNX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like RGNX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching RGNX by allowing them to research RGNX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree RGNX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
REGENXBIO (RGNX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

RIGL Shares Outstanding History
RLAY Shares Outstanding History
RLMD Shares Outstanding History
RLYB Shares Outstanding History
RMD Shares Outstanding History
RMED Shares Outstanding History
RMTI Shares Outstanding History
RNA Shares Outstanding History
RNAC Shares Outstanding History
RNAZ Shares Outstanding History
More Healthcare companies »

 

RGNX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2024, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 8.3%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 8.3%.